{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:50:54Z","timestamp":1785552654011,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175036"],"award-info":[{"award-number":["175036"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-9\/2021-14\/200161"],"award-info":[{"award-number":["451-03-9\/2021-14\/200161"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02085-5","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T20:02:13Z","timestamp":1680724933000},"page":"2309-2317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The phenotype of Graves\u2019 orbitopathy is associated with thyrotropin receptor antibody levels"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8885","authenticated-orcid":false,"given":"M.","family":"Sari\u0107 Matutinovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u017darkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"\u0106iri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ignjatovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nedeljkovi\u0107 Beleslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"2085_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101620","author":"ACH Lee","year":"2022","unstructured":"Lee ACH, Kahaly GJ (2022) Pathophysiology of thyroid-associated orbitopathy. Best Pract Res Clin Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.beem.2022.101620","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2085_CR2","volume-title":"Graves\u2019 Orbitopathy: a multisciplinary approach","author":"AJ Dickinson","year":"2017","unstructured":"Dickinson AJ (2017) Clinical manifestations. In: Wiersinga WM, Kahaly GJ (eds) Graves\u2019 Orbitopathy: a multisciplinary approach. Karger, Basel"},{"key":"2085_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1089\/thy.2015.0031","volume":"25","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S et al (2015) Prevalence, phenotype, and psychosocial well-being in euthyroid\/hypothyroid thyroid-associated orbitopathy. Thyroid 25:942\u2013948","journal-title":"Thyroid"},{"key":"2085_CR4","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, rrisk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol 11:615993","journal-title":"Front Endocrinol"},{"key":"2085_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current Insights into the Pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res 47:773\u2013778","journal-title":"Horm Metab Res"},{"key":"2085_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738","journal-title":"N Engl J Med"},{"key":"2085_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/08916938808997170","volume":"1","author":"DD Adams","year":"1988","unstructured":"Adams DD (1988) Long-acting thyroid stimulator: how receptor autoimmunity was discovered. Autoimmunity 1:3\u20139","journal-title":"Autoimmunity"},{"key":"2085_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4158\/EP-2019-0363","volume":"26","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ, Diana T, Olivo PD (2020) TSH receptor antibodies: relevance & utility. Endocr Pract 26:97\u2013106","journal-title":"Endocr Pract"},{"key":"2085_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40618-020-01380-9","volume":"44","author":"T Diana","year":"2021","unstructured":"Diana T, Ponto KA, Kahaly GJ (2021) Thyrotropin receptor antibodies and Graves\u2019 orbitopathy. J Endocrinol Invest 44:703\u2013712","journal-title":"J Endocrinol Invest"},{"key":"2085_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fendo.2017.00028","volume":"8","author":"GJ Kahaly","year":"2017","unstructured":"Kahaly GJ, Diana T (2017) TSH Receptor antibody functionality and nomenclature. Front Endocrinol 8:28","journal-title":"Front Endocrinol"},{"key":"2085_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","volume":"52","author":"MN Gerding","year":"2000","unstructured":"Gerding MN, Van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves\u2019 ophthalmopathy. Clin Endocrinol 52:267\u2013271","journal-title":"Clin Endocrinol"},{"key":"2085_CR12","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C (2021) The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43-67","journal-title":"Eur J Endocrinol"},{"key":"2085_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","volume":"55","author":"AJ Dickinson","year":"2001","unstructured":"Dickinson AJ, Perros P (2001) Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55:283\u2013303","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2085_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/BF03346614","volume":"33","author":"TJ Smith","year":"2010","unstructured":"Smith TJ (2010) Pathogenesis of Graves\u2019 orbitopathy: a 2010 update. J Endocrinol Invest 33:414\u2013421","journal-title":"J Endocrinol Invest"},{"key":"2085_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European thyroid association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J 7:167\u2013186","journal-title":"Eur Thyroid J"},{"key":"2085_CR16","doi-asserted-by":"publisher","first-page":"e13608","DOI":"10.1111\/ijcp.13608","volume":"74","author":"B Nedeljkovic Beleslin","year":"2020","unstructured":"Nedeljkovic Beleslin B, Ciric J, Stojkovic M, Savic S, Lalic T, Stojanovic M et al (2020) Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves\u2019 orbitopathy. Int J Clin Pract 74:e13608","journal-title":"Int J Clin Pract"},{"key":"2085_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman C (1987) Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 16:391\u2013407","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2085_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1530\/EJE-18-0039","volume":"178","author":"W Wiersinga","year":"2018","unstructured":"Wiersinga W, \u017darkovi\u0107 M, Bartalena L, Donati S, Perros P, Okosieme O et al (2018) EUGOGO (European Group on Graves\u2019 Orbitopathy). Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism. Eur J Endocrinol 178:635\u2013643. https:\/\/doi.org\/10.1530\/EJE-18-0039","journal-title":"Eur J Endocrinol"},{"key":"2085_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Grave\u2019s ophthalmopathy. Clin Endocrinol (Oxf) 47:9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2085_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2249.2010.04266.x","volume":"162","author":"SD Lytton","year":"2010","unstructured":"Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ (2010) Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 162:438\u2013446","journal-title":"Clin Exp Immunol"},{"key":"2085_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1309\/AJCPZUT7CNUEU7OP","volume":"139","author":"JJ Leschik","year":"2013","unstructured":"Leschik JJ, Diana T, Olivo PD, K\u00f6nig J, Krahn U, Li Y et al (2013) Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 139:192\u2013200","journal-title":"Am J Clin Pathol"},{"key":"2085_CR22","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, Neuh\u00e4user M, Mann K, Lederbogen S et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"2085_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40618-021-01652-y","volume":"45","author":"M Sari\u0107 Matutinovi\u0107","year":"2022","unstructured":"Sari\u0107 Matutinovi\u0107 M, Diana T, Nedeljkovi\u0107 Beleslin B, \u0106iri\u0107 J, \u017darkovi\u0107 M, Kahaly GJ et al (2022) Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves\u2019 orbitopathy. J Endocrinol Invest 45:189\u2013197. https:\/\/doi.org\/10.1007\/s40618-021-01652-y","journal-title":"J Endocrinol Invest"},{"key":"2085_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5937\/jomb0-34718","volume":"41","author":"M Sari\u0107-Matutinovi\u0107","year":"2022","unstructured":"Sari\u0107-Matutinovi\u0107 M, Diana T, Nedeljkovi\u0107-Beleslin B, \u0106iri\u0107 J, \u017darkovi\u0107 M, Perovi\u0107-Blagojevi\u0107 I et al (2022) Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy. J Med Biochem 41:211\u2013220. https:\/\/doi.org\/10.5937\/jomb0-34718","journal-title":"J Med Biochem"},{"key":"2085_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000266782","volume":"21","author":"WM Wiersinga","year":"1989","unstructured":"Wiersinga WM, Smit T, van der Gaag R, Mourits M, Koornneef L (1989) Clinical presentation of Graves\u2019 ophthalmopathy. Ophthalmic Res 21:73\u201382","journal-title":"Ophthalmic Res"},{"key":"2085_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/archopht.1993.01090020051022","volume":"111","author":"DL Kendler","year":"1993","unstructured":"Kendler DL, Lippa J, Rootman J (1993) The initial clinical characteristics of Graves\u2019 orbitopathy vary with age and sex. Arch Ophthalmol 111:197\u2013201","journal-title":"Arch Ophthalmol"},{"key":"2085_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","volume":"87","author":"TJ Smith","year":"2002","unstructured":"Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP et al (2002) Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385\u2013392","journal-title":"J Clin Endocrinol Metab"},{"key":"2085_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.autrev.2017.12.012","volume":"17","author":"A Bruscolini","year":"2018","unstructured":"Bruscolini A, Sacchetti M, La Cava M, Nebbioso M, Iannitelli A, Quartini A et al (2018) Quality of life and neuropsychiatric disorders in patients with Graves\u2019 orbitopathy: current concepts. Autoimmun Rev 17:639\u2013643","journal-title":"Autoimmun Rev"},{"key":"2085_CR29","unstructured":"Anderton LC, Neoh C, Walshaw D, Dickinson AJ. 2000 Reproducibility of clinical assessment in thyroid eye disease. Abstract of the European Society of the Ophthalmic Plastic and Reconstructive Surgery. Paris"},{"key":"2085_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40618-019-01141-3","volume":"43","author":"M Marin\u00f2","year":"2020","unstructured":"Marin\u00f2 M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R et al (2020) Orbital diseases mimicking Graves\u2019 orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest 43:401\u2013411","journal-title":"J Endocrinol Invest"},{"key":"2085_CR31","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1210\/jc.2018-02705","volume":"104","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ, W\u00fcster C, Olivo PD, Diana T (2019) High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves\u2019 disease. J Clin Endocrinol Metab 104:2561\u20132568. https:\/\/doi.org\/10.1210\/jc.2018-02705","journal-title":"J Clin Endocrinol Metab"},{"key":"2085_CR32","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","volume":"118","author":"KA Ponto","year":"2011","unstructured":"Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ (2011) Clinical relevance of thyroid-stimulating immunoglobulins in Graves\u2019 ophthalmopathy. Ophthalmology 118:2279\u20132285. https:\/\/doi.org\/10.1016\/j.ophtha.2011.03.030","journal-title":"Ophthalmology"},{"key":"2085_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","volume":"44","author":"F Nicol\u00ec","year":"2021","unstructured":"Nicol\u00ec F, Lanzolla G, Mantuano M, Ionni I, Mazzi B, Leo M et al (2021) Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy. J Endocrinol Invest 44:581\u2013585. https:\/\/doi.org\/10.1007\/s40618-020-01353-y","journal-title":"J Endocrinol Invest"},{"key":"2085_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1365-2265.2004.02033.x","volume":"60","author":"SY Goh","year":"2004","unstructured":"Goh SY, Ho SC, Seah LL, Fong KS, Khoo DH (2004) Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves\u2019 disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol 60:600\u2013607","journal-title":"Clin Endocrinol"},{"key":"2085_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/thy.1994.4.217","volume":"4","author":"R Volpe","year":"1994","unstructured":"Volpe R (1994) Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4:217\u2013223. https:\/\/doi.org\/10.1089\/thy.1994.4.217","journal-title":"Thyroid"},{"key":"2085_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/678194","author":"E Kampmann","year":"2015","unstructured":"Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ (2015) Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active Graves\u2019 orbitopathy: a prospective study. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2015\/678194","journal-title":"Int J Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02085-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T01:08:17Z","timestamp":1696640897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02085-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02085-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The JGU Medical Center receives research-associated funding from GJK and GJK consults for Quidelortho, USA. M\u017d is a member of the editorial board of the Journal of the Endocrinological Investigation. MSM, J\u0106, SI and BNB have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All patients signed an informed consent upon admission and Ethics Committee approval (944\/3: 17.06.2019.) was obtained prior to the study. Principles of good clinical and laboratory practice, the Declaration of Helsinki, and applicable national and institutional regulations were followed during this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed an informed consent upon admission and Ethics Committee approval (944\/3: 17.06.2019.) was obtained prior to the study. Principles of good clinical and laboratory practice, the Declaration of Helsinki, and applicable national and institutional regulations were followed during this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}